Current role of ultrasound for the management of hepatocellular carcinoma

Table 2 Assessment of therapeutic response after percutaneous treatment for HCC using contrast-enhanced US

Author	Treatment	No. of patients/No. of lesions	Results1 (contrast agent)
Bartolozzi et al[102]	PEI	40/47	Sensitivity 92%
			Specificity 100%
			Accuracy 98%
			(Levovist)
Wen et al[103]	RFA	67/91	Sensitivity 95.30%
			Specificity 100%
			Accuracy 98.10%
			(Levovist)
Meloni et al[104]	RFA	25/43	Sensitivity 83.30%
			Specificity 100%
			(Levovist)
Choi et al[105]	RFA	40/45	Diagnostic agreement 100%
			(Levovist)
Kim et al[106]	RFA	90/94	Diagnostic concordace2 99%
			(Levovist)
Solbiati et al[107]	RFA	20/203	Sensitivity 50%
			Specificity 100%
			Diagnostic agreement 85%
			(Levovist)
Pompili et al[110]	PEI, RFA, TACE	47/56	Sensitivity 87%
	Combined treatments		Specificity 98.40%
			Diagnostic agreement 94.60%
			(SonoVue)

¹Comparison with contrast-enhanced helical CT;

²1-mo follow-up CT;

³Solitary colorectal liver metastases.